Healthcare provider profile · identity verified

Richard L Goodwin, MD

Family Practice · NORTHFIELD, MN · NPI 1417911546

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1130	287
Amlodipine Besylate	Amlodipine Besylate	648	182
Lisinopril	Lisinopril	553	145
Omeprazole	Omeprazole	506	128
Losartan Potassium	Losartan Potassium	384	112
Rosuvastatin Calcium	Rosuvastatin Calcium	365	115
Levothyroxine Sodium	Levothyroxine Sodium	353	80
Tamsulosin Hcl	Tamsulosin Hcl	321	89
Hydrochlorothiazide	Hydrochlorothiazide	307	90
Glipizide Er	Glipizide	275	64
Metformin Hcl Er	Metformin Hcl	237	69
Metoprolol Succinate	Metoprolol Succinate	236	69
Eliquis	Apixaban	233	45
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	218	58
Warfarin Sodium	Warfarin Sodium	218	47
Metformin Hcl	Metformin Hcl	211	51
Metoprolol Tartrate	Metoprolol Tartrate	201	52
Allopurinol	Allopurinol	181	43
Furosemide	Furosemide	180	52
Potassium Chloride	Potassium Chloride	178	49
Atenolol	Atenolol	157	37
Carvedilol	Carvedilol	153	37
Famotidine	Famotidine	140	45
Gabapentin	Gabapentin	123	37
Sertraline Hcl	Sertraline Hcl	118	30
Alendronate Sodium	Alendronate Sodium	109	36
Fluticasone Propionate	Fluticasone Propionate	105	42
Trulicity	Dulaglutide	98	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	96	23
Spironolactone	Spironolactone	96	28
Albuterol Sulfate Hfa	Albuterol Sulfate	95	51
Pantoprazole Sodium	Pantoprazole Sodium	94	23
Ezetimibe	Ezetimibe	88	30
Clopidogrel	Clopidogrel Bisulfate	84	22
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	79	19
Jardiance	Empagliflozin	79	23
Pregabalin	Pregabalin	74	14
Pravastatin Sodium	Pravastatin Sodium	62	17
Mirtazapine	Mirtazapine	61	24
Fluoxetine Hcl	Fluoxetine Hcl	59	12
Chlorthalidone	Chlorthalidone	58	15
Finasteride	Finasteride	57	17
Triamcinolone Acetonide	Triamcinolone Acetonide	55	36
Lorazepam	Lorazepam	52	18
Trazodone Hcl	Trazodone Hcl	50	14
Prednisone	Prednisone	49	28
Montelukast Sodium	Montelukast Sodium	47	15
Mounjaro	Tirzepatide	47	11
Oxycodone Hcl	Oxycodone Hcl	46	15
Torsemide	Torsemide	46	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	46	15
Citalopram Hbr	Citalopram Hydrobromide	45	12
Farxiga	Dapagliflozin Propanediol	45	11
Pioglitazone Hcl	Pioglitazone Hcl	43	12
Simvastatin	Simvastatin	43	14
Tramadol Hcl	Tramadol Hcl	42	11
Bupropion Xl	Bupropion Hcl	41	12
Xarelto	Rivaroxaban	41	11
Duloxetine Hcl	Duloxetine Hcl	40	suppressed
Cephalexin	Cephalexin	38	26
Escitalopram Oxalate	Escitalopram Oxalate	36	14
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	36	12
Paroxetine Hcl	Paroxetine Hcl	36	suppressed
Amoxicillin	Amoxicillin	34	17
Ozempic	Semaglutide	33	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	32	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	31	suppressed
Labetalol Hcl	Labetalol Hcl	31	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	31	suppressed
Nitroglycerin	Nitroglycerin	29	21
Entresto	Sacubitril/Valsartan	28	suppressed
Glipizide	Glipizide	28	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	27	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Celecoxib	Celecoxib	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	21	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Trospium Chloride	Trospium Chloride	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Glimepiride	Glimepiride	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	17	suppressed
Primidone	Primidone	17	suppressed
Ulticare Pen Needle	Pen Needle, Diabetic	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	17	suppressed
Azithromycin	Azithromycin	16	16
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Klor-Con M20	Potassium Chloride	16	suppressed
Memantine Hcl	Memantine Hcl	16	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Amiodarone Hcl	Amiodarone Hcl	15	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	14	suppressed
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Incruse Ellipta	Umeclidinium Bromide	14	suppressed
Methylphenidate Er	Methylphenidate Hcl	14	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Insulin Aspart Flexpen	Insulin Aspart	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Methylprednisolone	Methylprednisolone	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Topiramate	Topiramate	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Dulera	Mometasone/Formoterol	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Linzess	Linaclotide	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Valsartan	Valsartan	12	suppressed
Repaglinide	Repaglinide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error